MIAMI, Fla. -- Tiger Woods was named this week’s AstraZeneca Charity Challenge winner for his first-place standing entering the final round of the Ford Championship at Doral. The AstraZeneca Charity Challenge, formerly known as the CRESTOR® Charity Challenge, is a season-long competition that recognizes and rewards the tournament leader entering the final round at 35 PGA TOUR events. Through the sponsorship, AstraZeneca will donate $3.5 million this year to designated health care charities and will have donated a three-year total of $9.7 million by the conclusion of the 2006 PGA TOUR season.

AstraZeneca produces a wide range of products that make significant contributions to treatment options and patient care including CRESTOR, NEXIUM, SEROQUEL, ARIMIDEX, and PULMICORT RESPULES. Through this year’s sponsorship, as part of its commitment to patient health and well being, AstraZeneca will also designate health care related charities across therapeutic areas as recipients at the 35 PGA TOUR events throughout the year.

For Woods’ performance, AstraZeneca will donate $100,000 to National Mental Health Association (NMHA) on behalf of Woods and the Ford Championship at Doral. “As the country’s oldest and largest nonprofit organization devoted to mental health, NMHA has dedicated nearly 100 years to support the mental well-being of every American through advocacy, education, and service,” said Eileen T. Sexton, Vice President, Media Relations, NMHA. “NMHA and its network of more than 340 affiliates nationwide are grateful for the generous support from AstraZeneca to further NMHA’s mission.”

“AstraZeneca’s partnership with the PGA TOUR is an integral part of our mission of giving back in local communities throughout America,” said Tony Zook, CEO, AstraZeneca U.S. “The AstraZeneca Charity Challenge offers a unique platform for providing important disease awareness, health information and education to make a difference in the lives of patients and consumers everyday.”

The AstraZeneca Charity Challenge is the centerpiece of a multi-year PGA TOUR partnership with AstraZeneca (NYSE:AZN). Last year, AstraZeneca donated $3.5 million through the program. Highlights from the AZCC include:
•Two weeks ago, the AstraZeneca Charity Challenge winner at the Nissan Open was Rory Sabbatini
• At six (6) of the first six (7) tournaments of 2006, the AstraZeneca Charity Challenge winner or co-winner went on to win the tournament
•More than 85 charities have benefited from the program
• Vijay Singh leads all players with eight AstraZeneca Charity Challenge wins. With some of his charitable “winnings,” Singh donated money to the American Red Cross Hurricane Relief Funds in Florida and New Orleans
•Other multiple winners have included Tom Lehman (four), Chad Campbell, Sergio Garcia, Phil Mickelson and David Toms (three), and the following players who triumphed twice: Stuart Appleby, Bart Bryant, Chris DiMarco, Luke Donald, Jim Furyk, Arron Oberholser, Joe Ogilvie, Rod Pampling, Kenny Perry, Carl Petterson, Ted Purdy, and Adam Scott.

Fans can log on to www.astrazeneca.pgatour.com to read about past AstraZeneca Charity Challenge winners and learn more about AstraZeneca.

About NMHA (National Mental Health Association) The National Mental Health Association is the country’s oldest and largest non-profit organization addressing all aspects of mental health and mental illness. With more than 340 affiliates nationwide, NMHA works to improve the mental health of all Americans through advocacy, education, research and service.

About AstraZeneca AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of over $21.4 billion and leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology and neuroscience products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. Worldwide, AstraZeneca has six major research and development sites, four discovery facilities and a clinical research site. In total, AstraZeneca’s R&D organization is comprised of more 11,500 people located in seven countries including Canada, France, India, Japan, Sweden, United Kingdom and the United States.